#China #Shanghai #Inc. #American Depositary Shares #111 #healthcare platform

111, Inc. Announces Major Adjustment in ADS Ratio

On January 8, 2025, 111, Inc. (NASDAQ: YI), a prominent digital healthcare platform in China, declared a significant modification in the ratio of its American Depositary Shares (ADS) to its Class A ordinary shares. This change reflects the company's ongoing commitment to optimizing its trading mechanisms and enhancing shareholder value.

New ADS Ratio Details

Previously, the ratio of one ADS to two Class A shares will now be altered to one ADS representing twenty Class A shares. This adjustment will effectively function as a one-for-ten reverse split of the ADS. It's important to note that this change will not affect the underlying Class A shares directly, and no shares will be created or removed as a consequence of this ratio adjustment.

For existing ADS holders, this transition will be executed seamlessly, requiring no action from shareholders. The operational specifics will be handled automatically through the ADS depositary's records. The change is anticipated to be in effect when the market opens on January 24, 2025.

Impact on Trading Price and Market Perception

The adjustment in the ADS ratio is expected to result in a proportionate increase in the ADS trading price. However, the company has clarified that there can be no guarantee regarding the post-ratio change price level, and investors should be aware of the inherent risks associated with market fluctuations. Potential developments in the ADS price could vary significantly based on trading conditions and market sentiment following the change.

Legal disclaimers related to forward-looking statements have also been issued, signifying the company's awareness of the uncertainties involved in these market predictions. Statements about future earnings, operational strategies, and growth expectations fall into this category, reflecting the company's current outlook and market conditions.

Overview of 111, Inc.

111, Inc. is recognized for its innovative approach to healthcare in China, aspiring to revolutionize the healthcare experience by integrating digital tools into the value chain. The company facilitates better access to pharmaceuticals and healthcare services through its online platform, 1 Pharmacy, and its expansive offline virtual pharmacy network.

In addition to retail offerings, the company operates 1 Clinic, an online healthcare service that provides patients with comprehensive medical consultations, electronic prescriptions, and patient management efficiently and affordably. The 1 Medicine platform enhances access for pharmacies seeking a broad selection of pharmaceutical products, thereby enriching the overall healthcare ecosystem.

As the largest virtual pharmacy network in China, 111 enables traditional pharmacies to adopt cloud-based services for improved customer satisfaction. The company also offers various promotional and digital marketing services, underscoring its ambitious strategy to grow within the broader healthcare market.

For further updates and insights about 111, Inc. and its ongoing initiatives, interested parties are encouraged to visit the company's official website at ir.111.com.cn.

In conclusion, the ADS ratio change represents a strategic decision that aligns with 111, Inc.'s overarching goal of enhancing trading dynamics, positioning itself advantageously within the rapidly evolving digital healthcare landscape in China. Investors should remain informed of potential shifts in the market atmosphere as the division unfolds.